Health Care: Drugs

Acasti Pharma Inc (ACST: NASDAQ)

$0.5643 0.0163 | 2.97%
10/20/14 - 03:56 PM ET
Company Cash Flow
Feb 2014 Feb 2013 Feb 2012 Feb 2011
Cash Flow From Operating Activities
Net Income (Loss) -10.44M -6.73M -6.54M -2.43M
Operating Gains/Losses 0.00 0.00 -12.86K 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -282.47K 241.06K -640.35K 25.08K
(Increase) Decrease in Inventories -35.33K 368.58K -602.93K 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -78.23K 1.16M 186.66K 391.16K
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 0.00 0.00 0.00 0.00
Other Non-Cash Items 3.74M 1.80M 1.32M 108.14K
Net Cash From Continuing Operations -6.12M -2.49M -5.65M -1.90M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -6.12M -2.49M -5.65M -1.90M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 5.39M 1.95M 4.53M 0.00
Purchases of Property, Plant & Equipment -133.56K -100.68K 0.00 -21.58K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -22.82M 0.00 -7.54M 0.00
Other Cash from Investing Activities 88.20K 1.74K 8.17K 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -17.48M 1.85M -3.01M -2.59M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 873.74K 224.15K 9.95M 4.40M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 21.56M -2.62K -9.01K 0.00
Net Cash From Financing Activities 22.44M 221.53K 9.94M 4.40M
Effect of Exchange Rate Changes 689.10K 29.45K -9.54K 0.00
Net Change in Cash & Cash Equivalents -468.32K -384.12K 1.27M -92.68K
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter